Renexxion is Drug Discovery in United States that focus on enteral feeding intolerance business. Founded in 2014. They cover business area such as developer, naronapride drug, gastrointestinal disorder, an oral gastro-prokinetic drug, chronic idiopathic constipation, functional dyspepsia, gastroparesis, gastroesophageal reflux disease, short bowel syndrome, SBS, enteral feeding intolerance, post-operative illus, doctor.
2014
( 10 years old in 2024 )
Enteral Feeding Intolerance
-
325 Sharon Park Drive
Suite 303
Menlo Park, CA 94025
United States
Private
developernaronapride druggastrointestinal disorderan oral gastro-prokinetic drugchronic idiopathic constipationfunctional dyspepsiagastroparesisgastroesophageal reflux diseaseshort bowel syndromeSBSenteral feeding intolerancepost-operative illusdoctor
* We use standard office opening hours in near Renexxion's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Renexxion is Drug Discovery business from United States that founded in 2014 (10 years old in 2024), Renexxion business is focusing on Enteral Feeding Intolerance.
Renexxion headquarter office and corporate office address is located in 325 Sharon Park Drive Suite 303 Menlo Park, CA 94025 United States.
Renexxion was founded in United States.
In 2024, Renexxion is currently focus on enteral feeding intolerance sector.
Above is snippet of Google Trends for "enteral feeding intolerance" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Renexxion, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
